www.fdanews.com/articles/177754-abbvies-viekira-xr-gets-green-light-from-fda
AbbVie’s Viekira XR Gets Green Light From FDA
August 1, 2016
The FDA has granted approval to AbbVie’s Viekira XR, which is for patients with hepatitis C virus.
The three-pill antiviral treatment was approved after Phase 3 studies showed 100 percent sustained virologic response 12 weeks after treatment in hepatitis C patients with chronic genotype 1.
The extended release tablets contain the following four active ingredients: ombitasvir, paritaprevir, ritonavir tablets and dasabuvir.